KRBP Kiromic BioPharma, Inc.

Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. Its technologies include Intelligent Immunotherapy, Diamond AI, CancerSplice, ABBIE, and CAR-T Proprietary Binder Technology. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

$4.11  +0.15 (3.66%)
As of 03/24/2023 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/15/2020
Outstanding shares:  20,504,701
Average volume:  2,407,193
Market cap:   $81,301,139
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%